Search

Your search keyword '"Etanercept -- Product development"' showing total 36 results
Start Over Descriptor "Etanercept -- Product development" Database Gale General OneFile
36 results on '"Etanercept -- Product development"'

1. Lupin's JV yields positive results for Etanercept clinical trials

Subjects
Etanercept -- Product development, Rheumatoid factor, Clinical trials, Arthritis, Company business management, Automobile industry
Abstract

YL Biologics (YLB), a joint venture by drugmaker Lupin and Yoshindo, has successfully completed the late phase clinical studies on a biosimilar version of Etanercept (YLB113). YLB is a joint [...]

Published
2018

3. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial

Author

Tyring, Stephen, Gottlieb, Alice, Papp, Kim, Gordon, Ken, Leonardi, Craig, Wang, Andrea, Lalla, Deepa, Woolley, Michael, Jahreis, Angelika, Zitnik, Ralph, Cella, David, and Krishnan, Ranga

Subjects
Psoriasis -- Drug therapy, Cytokines -- Physiological aspects, Etanercept -- Dosage and administration, Etanercept -- Patient outcomes, Etanercept -- Product development, Clinical trials -- Management, Company business management
Published
2006

4. Clover Biopharmaceuticals Initiates Phase III Study of Etanercept Biosimilar Candidate SCB-808 in China

Subjects
Clinical trials, Rheumatoid factor, Biopharmaceuticals -- Product development, Etanercept -- Product development, Syringes, Biological products, Ankylosing spondylitis, Arthritis, Antiarthritic agents, Spondylitis, Biotechnology industries, Business, international, Law, Enbrel (Medication)
Abstract

Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, today announced that the first patient was dosed in a Phase III trial of SCB-808, [...]

Published
2019

5. Clover Biopharmaceuticals Initiates Phase III Study of Etanercept Biosimilar Candidate SCB-808 in China

Subjects
Clinical trials, Rheumatoid factor, Biopharmaceuticals -- Product development, Etanercept -- Product development, Syringes, Biological products, Ankylosing spondylitis, Arthritis, Antiarthritic agents, Spondylitis, Biotechnology industries, Business, Business, international, Enbrel (Medication)
Abstract

BEIJING -- Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, today announced that the first patient was dosed in a Phase III trial [...]

Published
2019

6. Clover Initiates Phase 1 Trial of Proposed Etanercept Biosimilar

Subjects
Clinical trials, Rheumatoid factor, Medical research, Biological products -- Product development, Etanercept -- Product development, Business, international, Enbrel (Medication)
Abstract

China-based Clover Biopharmaceuticals recently announced that the first patient was dosed in a phase 1 trial of SCB-808, a potential etanercept (Enbrel) biosimilar. SCB-808 is being developed in a prefilled [...]

Published
2018

7. Clover Biopharmaceuticals Initiates Phase I Study of Etanercept Biosimilar Candidate SCB-808 in China

Subjects
Clinical trials, Rheumatoid factor, Biopharmaceuticals -- Product development, Biological products industry -- Product development, Etanercept -- Product development, Business, Business, international, Enbrel (Medication)
Abstract

CHENGDU, China -- Clover Biopharmaceuticals, a biotechnology company focused on developing novel and transformative biologic therapies, today announced that the first patient was dosed in a Phase I trial of [...]

Published
2018

8. Company News: Lupin's JV Yields Positive Results for Etanercept Clinical Trials

Subjects
Clinical trials, Rheumatoid factor, Etanercept -- Product development, Company business management, Biotechnology industry
Abstract

YL Biologics (YLB), a joint venture by drug maker Lupin and Yoshindo, has successfully completed the late phase clinical studies on a biosimilar version of Etanercept (YLB113). YLB is a [...]

Published
2018

9. Lupins JV yields positive results for Etanercept clinical trials

Subjects
Clinical trials, Rheumatoid factor, Etanercept -- Product development, Company business management, Business, international
Abstract

YL Biologics (YLB), a joint venture by drugmaker Lupin and Yoshindo, has successfully completed the late phase clinical studies on a biosimilar version of Etanercept (YLB113). YLB is a joint [...]

Published
2018

10. Lupin's JV yields positive results for Etanercept clinical trials

Subjects
Clinical trials, Rheumatoid factor, Etanercept -- Product development, Company business management, Biotechnology industry
Abstract

YL Biologics (YLB), a joint venture by drugmaker Lupin and Yoshindo, has successfully completed the late phase clinical studies on a biosimilar version of Etanercept (YLB113). YLB is a joint [...]

Published
2018

11. Lupin's JV completes global Phase III clinical trial of Etanercept biosimilar

Subjects
Pfizer Inc. -- Product development -- Joint ventures, Clinical trials, Rheumatoid factor, Pharmaceutical industry -- Product development -- Joint ventures, Etanercept -- Product development, Company joint venture, Business, international, Enbrel (Medication)
Abstract

The Phase III study was a multinational randomized double-blind controlled trial of 52 weeks duration which included more than 500 patients with RA in 11 countries Lupin's joint venture (JV) [...]

Published
2018

12. FDA granted an expanded indication for etanercept

Subjects
Amgen Inc. -- Product development, Psoriatic arthritis -- Drug therapy, Etanercept -- Product development, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries, Drug therapy, Product development
Abstract

FDA granted an expanded indication for etanercept (Enbrel, Amgen/Wyeth) to include improvement of physical function in patients with psoriatic [...]

Published
2005

13. Prospective study using remicade in psoriasis patients with an inadequate response to etanercept

Subjects
Centocor Inc. -- Product development, Psoriasis -- Drug therapy, Medical equipment and supplies industry -- Product development, Medical test kit industry -- Product development, Etanercept -- Dosage and administration, Etanercept -- Product development, Infliximab -- Dosage and administration, Infliximab -- Product development, Health, Pharmaceuticals and cosmetics industries
Abstract

Sponsored by Centocor, Inc. The purpose of this study is to test the safety and effectiveness of infliximab in patients with plaque psoriasis who have been receiving the drug etanercept [...]

Published
2009

14. Sandoz Canada Regulatory Submission for Subsequent Entry Biologic Etanercept Accepted for Review by Health Canada

Subjects
Sandoz Canada Inc. -- Product development, Tumor necrosis factor, Pharmaceutical industry -- Product development, Etanercept -- Product development, Business, general, Business, regional
Abstract

Jun 28, 2016 (Marketwired via COMTEX) -- BOUCHERVILLE, QC--(Marketwired - June 28, 2016) - Sandoz Canada announced today that Health Canada has accepted for review its regulatory submission for a [...]

Published
2016

15. Sandoz Canada Regulatory Submission for Subsequent Entry Biologic Etanercept Accepted for Review by Health Canada

Subjects
Sandoz Canada Inc. -- Product development, Tumor necrosis factor, Pharmaceutical industry -- Product development, Etanercept -- Product development, Business, Business, international, News, opinion and commentary
Abstract

Jun 28, 2016 (Marketwired via COMTEX) -- BOUCHERVILLE, QC--(Marketwired - June 28, 2016) - Sandoz Canada announced today that Health Canada has accepted for review its regulatory submission for a [...]

Published
2016

16. One Year Data from Phase III Study Evaluating Oral OTEZLA[R] (apremilast) or Injectable etanercept versus Placebo in Patients with Moderate to Severe Plaque Psoriasis Presented at EADV

Subjects
Celgene Corp. -- Product development, Medical research, Psoriasis, Pharmaceutical industry -- Product development, Etanercept -- Product development, Business, Business, international, Otezla (Medication)
Abstract

Improvements in PASI scores and disease-related quality of life observed at week 16 were maintained at week 52 in patients randomized to OTEZLA at baseline and in patients who switched [...]

Published
2015

17. Positive Results from Phase III Study Evaluating Oral OTEZLA[R] (Apremilast) or Injectable Etanercept versus Placebo in Patients with Moderate to Severe Plaque Psoriasis Presented at AAD

Subjects
Celgene Corp. -- Product development, Pharmaceutical industry -- Product development, Etanercept -- Product development, Business, Business, international, Otezla (Medication)
Abstract

Third phase III study with OTEZLA to demonstrate statistically significant improvements versus placebo for the primary and key secondary endpoints at week 16 More patients achieved a PASI-75 response at [...]

Published
2015

18. Japan : Initiation of Phase 3 Trial of CHS-0214 (Investigational Etanercept Biosimilar) in Japan (RApsody)

Subjects
Daiichi Sankyo Company Ltd. -- Product development, Etanercept -- Product development, Pharmaceutical industry -- Product development, Business, international
Abstract

Daiichi Sankyo Company, Limited today announced the start of the Phase 3 trial of CHS-0214, an investigational etanercept biosimilar, in rheumatoid arthritis (the RApsody trial) in Japan. Daiichi Sankyo is [...]

Published
2014

19. Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Chronic Plaque Psoriasis (RaPsOdy)

Subjects
Baxter International Inc. (Deerfield, Illinois) -- Product development, Psoriasis, Etanercept -- Product development, Medical test kit industry -- Product development, Medical equipment and supplies industry -- Product development, Business, News, opinion and commentary
Abstract

Company Advances Development as Part of Collaboration with Baxter International's Biopharmaceutical Business REDWOOD CITY, Calif., July 16, 2014 /PRNewswire/ -- http://www.coherus.com/ , Inc. announced the start of its Phase 3 [...]

Published
2014

20. Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Rheumatoid Arthritis

Subjects
Baxter International Inc. (Deerfield, Illinois) -- Product development, Etanercept -- Product development, Rheumatoid factor, Medical test kit industry -- Product development, Medical equipment and supplies industry -- Product development, Arthritis, Business, News, opinion and commentary
Abstract

Coherus Advances Development as Part of Collaboration with Daiichi Sankyo and Baxter REDWOOD CITY, Calif., June 23, 2014 /PRNewswire/ -- http://www.coherus.com/ , Inc. announced the start of its Phase 3 [...]

Published
2014

21. Use of etanercept in the treatment of moderate to severe Lichen planus

Subjects
Etanercept -- Dosage and administration, Etanercept -- Complications and side effects, Etanercept -- Product development, Lichen planus -- Drug therapy, Health, Pharmaceuticals and cosmetics industries
Abstract

Sponsored by Stanford University. Collaborators: Wright State University, Tufts Medical Center, University of Louisville, Wake Forest University, University of Michigan, Emory University, University Hospitals of Cleveland, Mount Sinai School of [...]

Published
2010

22. Lichen planus

Subjects
Pharmaceutical industry -- Product development, Etanercept -- Product development, Lichen planus -- Drug therapy, Health, Pharmaceuticals and cosmetics industries
Abstract

Use of etanercept in the treatment of moderate to severe lichen planus.Sponsored by Stand University; Wright State University; Tufts Medical Center; University of Louisville; Wake Forest University; University of Michigan; [...]

Published
2010

23. Trial of an injectable biologic and U0279 as combination therapy for severe plaque-type psoriasis

Subjects
GSK Pharma -- Product development, Psoriasis -- Drug therapy, Acitretin -- Dosage and administration, Acitretin -- Product development, Etanercept -- Product development, Etanercept -- Dosage and administration, Pharmaceutical industry -- Product development, Health, Pharmaceuticals and cosmetics industries
Abstract

Sponsored by Stiefel, a GSK Company. The purpose of the study is to assess the safety and efficacy of an injectable biologic and U0279 as combination therapy compared to that [...]

Published
2009

24. A study to evaluate the switch from etanercept to infliximab in subjects with moderate-to-severe psoriasis (study P05133)

Subjects
Schering-Plough Corp. -- Product development, Centocor Inc. -- Product development, Psoriasis -- Drug therapy, Infliximab -- Dosage and administration, Infliximab -- Product development, Etanercept -- Dosage and administration, Etanercept -- Product development, Pharmaceutical industry -- Product development, Medical equipment and supplies industry -- Product development, Medical test kit industry -- Product development, Health, Pharmaceuticals and cosmetics industries
Abstract

Sponsored by Schering-Plough; Centocor, Inc. This open-label, uncontrolled, single-group assignment study will evaluate the efficacy, tolerability and effect on the quality of life of infliximab in adults with moderate-to-severe psoriasis [...]

Published
2009

25. Study evaluating etanercept for the treatment of moderate-to-severe psoriasis (pristine)

Subjects
Etanercept -- Dosage and administration, Etanercept -- Product development, Psoriasis -- Drug therapy, Health, Pharmaceuticals and cosmetics industries
Abstract

Sponsored by Wyeth. The purpose of this randomized, double-blind, single group assignment, safety/efficacy study is to compare the safety and efficacy of different doses of etanercept for the treatment of [...]

Published
2009

26. A study to evaluate the satefy and effectiveness of etanercept in treating lichen planus on the oral mucosa or skin

Subjects
Etanercept -- Dosage and administration, Etanercept -- Product development, Lichen planus -- Drug therapy, Health, Pharmaceuticals and cosmetics industries, Stanford University -- Product development
Abstract

Sponsored by Stanford University. The purpose of this study is to determine the safety and efficacy of etanercept (also known as Enbrel) in the treatment of moderate-to-severe lichen planus. Etanercept [...]

Published
2009

27. A pilot study of etanercept in dermatomyositis

Subjects
United States. National Institute of Neurological and Communicative Disorders and Stroke -- Product development, Etanercept -- Dosage and administration, Etanercept -- Product development, Dermatomyositis -- Drug therapy, Dermatomyositis -- Research, Health, Pharmaceuticals and cosmetics industries
Abstract

Sponsored by Brigham and Women's Hospital; National Institute of Neurological Disorders and Stroke (NINDS). Dermatomyositis (DM) is an autoimmune disorder that affects skin and muscle. Autoimmune disorders are diseases in [...]

Published
2009

28. Positive Results from Phase III Study Evaluating Oral OTEZLA[R] Apremilast or Injectable Etanercept versus Placebo in Patients with Moderate to Severe Plaque Psoriasis Presented at AAD

Subjects
Celgene Corp. -- Product development, Pharmaceutical industry -- Product development, Etanercept -- Product development, Biotechnology industry, Pharmaceuticals and cosmetics industries, American Academy of Dermatology, Otezla (Medication)
Abstract

By a News Reporter-Staff News Editor at Biotech Week -- Celgene Corporation (NASDAQ:CELG) announced that results from its ongoing phase III LIBERATE trial evaluating Otezla® (apremilast), the Company's oral, selective [...]

Published
2015

29. A study of the safety and effectiveness of CNTO 1275 compared to etanercept for the treatment of moderate to severe plaque psoriasis

Subjects
Centocor Inc. -- Product development, Medical equipment and supplies industry -- Product development, Medical test kit industry -- Product development, Etanercept -- Product development, Psoriasis -- Drug therapy, Health, Pharmaceuticals and cosmetics industries
Abstract

Sponsored by Centocor, Inc. The purpose of this research study is to compare the effects (good and/or bad) of CNTO 1275 or etanercept on moderate to severe plaque psoriasis. Condition [...]

Published
2007

30. Safety and effectiveness of CNTO 1275 compared to etanercept for moderate to severe plaque psoriasis

Subjects
Centocor Inc. -- Product development, Medical equipment and supplies industry -- Product development, Medical test kit industry -- Product development, Etanercept -- Product development, Health, Pharmaceuticals and cosmetics industries, CNTO 1275 (Medication) -- Product development
Abstract

Sponsored by Centocor, Inc. The purpose of this research study is to compare the effects (good and/or bad) of CNTO 1275 or etanercept on moderate to severe plaque psoriasis. Condition [...]

Published
2007

31. Study of etanercept (Enbrel[R]) in the treatment of pemphigus vulgaris

Author

Johnson, Hillary

Subjects
Dermatologic agents -- Product development, Etanercept -- Product development, Dermatology -- Formulae, receipts, prescriptions, Dermatology -- Product development, Cooperative agreement for product development, Health, Pharmaceuticals and cosmetics industries, Massachusetts General Hospital -- Alliances and partnerships, Massachusetts General Hospital -- Product development, Stanford University -- Alliances and partnerships, Stanford University -- Product development, Enbrel (Medication) -- Product development
Abstract

Sponsors and Collaborators: Massachusetts General Hospital Brigham and Women's Hospital and Stanford University. The purpose of the study is to find out about the effectiveness and safety of an investigational [...]

Published
2007

32. Findings on Clinical Trials and Studies Detailed by M. Dougados and Co-Authors (Symptomatic Efficacy of Etanercept and Its Effects on Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis A Multicenter, Randomized, ...) ( ...)

Subjects
Medical research, Medicine, Experimental, Etanercept -- Product development, Clinical trials, Health
Abstract

By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators publish new report on Clinical Research. According to news reporting originating in Paris, France, by NewsRx journalists, research [...]

Published
2014

33. Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 Investigational Etanercept Biosimilar In Chronic Plaque Psoriasis RaPsOdy

Subjects
Psoriasis, Etanercept -- Product development, Biotechnology industry, Biological sciences, Business, Enbrel (Medication) -- Product development
Abstract

By a News Reporter-Staff News Editor at Biotech Business Week -- Coherus BioSciences , Inc. announced the start of its Phase 3 trial of CHS-0214, a proposed biosimilar of etanercept [...]

Published
2014

35. Ustekinumab bests etanercept in phase III study

Author

Jancin, Bruce

Subjects
Etanercept -- Product development, Clinical trials, Health, Health care industry
Abstract

SAN FRANCISCO -- Ustekinumab outperformed etanercept for treatment of psoriasis in the first-ever head-to-head comparison of the two biologic agents. The 12-week phase III multicenter trial involved 903 patients with [...]

Published
2009

36. Amgen Inc

Subjects
Wyeth Pharmaceuticals -- Alliances and partnerships -- Product development, Amgen Inc. -- Product development -- Alliances and partnerships, Etanercept -- Product development, Antirheumatic agents -- Product development, Methotrexate -- Product development, Pharmaceutical industry -- Alliances and partnerships -- Product development, Cooperative agreement for product development, Business, Chemicals, plastics and rubber industries, Enbrel (Medication) -- Product development
Abstract

AMGEN Inc. and Wyeth Pharmaceuticals, a division of Wyeth, announced that data from a long-term study of anti-tumor necrosis factor (anti-TNF) agent in rheumatoid arthritis showed no progression of joint [...]

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results